Australia's most trusted
source of pharma news
Posted 26 April 2024 AM
Eli Lilly is on the cusp of redefining "big" when it comes to revenue with its blockbuster drug Mounjaro expected to bring in as much in 2029 as the company's entire portfolio brought in last year.
According to Global Data analysts, in five years Mounjaro will hit sales of US$34 billion - the same dollar figure the company made from sales of every product it owns in 2023. The icing on top will be Lilly's success in Alzheimer's disease with the company's donanemab set to be a 'game-changer'.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.